Injection Drug Use
Injection Drug Use - Related Videos
10:28
An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
0 Views •
Cited by 21 •
2015
Supramolecular hydrogelators based on ureido-pyrimidinones allow full control over the macroscopic gel properties and the sol–gel switching behavior using pH. Here, we present a protocol for formulating and injecting such a supramolecular hydrogelator via a catheter delivery system for local delivery directly in relevant areas in the pig heart.
11:28
3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
0 Views •
Cited by 7 •
2017
This protocol describes the fabrication of elastic 3D macroporous microcryogels by integrating microfabrication with cryogelation technology. Upon loading with cells, 3D microtissues are generated, which can be readily injected in vivo to facilitate regenerative therapy or assembled into arrays for in vitro high-throughput drug screening.
03:30
Targeted Drug Delivery in a Mouse Model via Cisterna Magna Injection
0 Views •
2025
Source: Zamboni, M., et al., Induction of Leptomeningeal Cells Modification Via Intracisternal Injection. J. Vis. Exp. (2020)This video demonstrates the procedure of delivering an inducer drug into the cisterna magna of an anesthetized mouse. The injection selectively induces fluorescent marker expression in brain surface cells accessible via cerebrospinal fluid, confirmed by fluorescence imaging.
05:04
An Ultrasound-Guided Injection of Therapeutic Drugs into Human Salivary Glands
0 Views •
2025
The video demonstrates an ultrasound-guided injection technique for administering therapeutic drugs into the salivary glands of a human patient.
05:10
Intrarenal Drug Delivery in Rats: A Method to Deliver Therapeutic Drugs in Rat Kidney via Intra-arterial Injection
0 Views •
2023
In this video, we demonstrate intra-renal drug administration in rats via the renal artery. This method is beneficial in improving drug targeting, drug potency, and minimizing systemic toxicity.
FAQs
Injection bypasses the gastrointestinal tract, so a substance can reach the bloodstream or surrounding tissue without first passing through digestion. This can increase the fraction available to the body, called bioavailability, and shorten the time to systemic effects. Clinically, the same rapid delivery can narrow the margin between intended effects and overdose, making prevention and monitoring important.
Repeated needle use can injure blood vessels and damage injection sites in the skin or other soft tissue. These local effects are clinically important because they may occur alongside skin and soft-tissue infections, rather than remaining only a behavioral concern. Examination of injection sites and attention to wounds therefore form part of appropriate clinical care.
Sharing injection equipment creates a route for blood-borne infection to pass between people. The overview specifically identifies HIV and hepatitis C as important examples. Risk assessment should therefore ask about equipment sharing in a nonjudgmental way and connect patients with infectious-disease testing, while sterile equipment access addresses a preventable pathway of transmission.
Clinical screening should be nonjudgmental and should address more than the substance itself. Relevant concerns include overdose risk, injection-related vascular or soft-tissue complications, equipment sharing, and possible HIV or hepatitis C. This broader assessment helps clinicians identify immediate clinical needs and select prevention, testing, wound care, or substance-use treatment responses appropriate to the patient.
Overdose prevention and sterile equipment access are complementary clinical services. The first focuses on reducing harms associated with rapid systemic delivery, while the second helps reduce exposure to blood-borne infection through shared equipment. Together with nonjudgmental engagement, they support connection with care and create opportunities for infectious-disease testing and treatment.
When injection causes a wound or soft-tissue problem, wound management becomes a direct clinical priority rather than an optional add-on. Care also includes evidence-based treatment for substance use disorders, allowing clinicians to address both an immediate physical complication and the ongoing condition associated with repeated use. This combined approach reflects the range of consequences described in clinical practice.